Antibody specificity transfer using minimal essential binding determinants

US7981843B2 · kind B2 · utility

Assignee

• KaloBios Pharmaceuticals, Inc. · US

Inventors

• Peter Flynn · San Diego, US
• Kenneth Luehrsen · Rue de l'Église, US
• Robert Balint · Palo Alto, US
• Jeng-Horng Her · San Jose, US
• Christopher R. Bebbington · San Mateo, US
• Geoffrey T. Yarranton · Burlingame, US

Key dates

• Filing date: Jan 20, 2005
• Grant date: Jul 19, 2011
• Expiry date: Jan 20, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.